Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?

BioNTech's stock has fallen 63.3% over 5 years, raising questions about its valuation. Recent Phase 3 lung cancer trial data showed promising results, potentially boosting long-term revenue expectations. The company trades at 8.3x P/S, lower than peers. Analysts are divided on whether the oncology pipeline justifies the current valuation, with bulls seeing 16% undervaluation and bears citing 18% overvaluation due to declining COVID-19 vaccine demand.

Pfizer will pay $44M to settle a class action lawsuit alleging it misrepresented Chantix's safety before a recall due to contamination. The settlement covers U.S. retail purchases from 2015 to 2021. Chantix, approved in 2006, is a smoking-cessation drug.

Apple led The Irish Times' Top 1,000 rankings with €209.3bn revenue and €72bn profit. Microsoft, Meta, and Google followed. Eli Lilly entered the top 10. CRH was the largest indigenous company. Apple and Meta reduced Irish headcounts. Irish corporation taxes surged due to tech profits.

The FDA is scrutinizing REGENXBIO's RGX-202 and Solid Biosciences' SGT-003, both Duchenne muscular dystrophy treatments, for accelerated approval. The FDA requires evidence that microdystrophin expression predicts clinical benefit, citing Pfizer's failed CIFFREO trial as a cautionary example. REGENXBIO reported 93% of patients reached 10% microdystrophin expression, but functional data is limited. The FDA seeks robust evidence before approval, given the permanent nature of gene therapy.

Karnataka FDA revoked 16 pharmacy licenses, suspended 8, and Pfizer's distribution center license amid a counterfeit drug probe. Fake drugs worth ₹5.05 crore were seized. Pfizer stated it is cooperating with authorities, prioritizing patient safety and product quality.

BioNTech (BNTX) reported mixed clinical trial results. Its colorectal cancer vaccine, autogene cevumeran, failed in a Phase 2 trial, causing a 10% stock drop. However, its lung cancer treatment, Gotistobart, showed promising early Phase 3 results with a median overall survival of 18.5 months. The company's future depends on upcoming clinical trials, including BNT113 for head and neck cancer, which has received FDA Fast Track designation.